Novo Nordisk A S annual working capital
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Working Capital Growth & History (NVO)
Novo Nordisk A S's working capital was −kr43.21B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −kr43.21B | kr12.62B | — |
| 2024 | 2024-12-31 | −kr55.83B | −kr25.82B | — |
| 2023 | 2023-12-31 | −kr30.01B | −kr17.26B | — |
| 2022 | 2022-12-31 | −kr12.75B | kr1.18B | — |
| 2021 | 2021-12-31 | −kr13.92B | −kr9.46B | — |
| 2020 | 2020-12-31 | −kr4.46B | −kr7.94B | — |
| 2019 | 2019-12-31 | kr3.47B | — | — |
Novo Nordisk A S quarterly working capital
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −kr30.39B | kr14.43B | — |
| Q1 2026 | 2026-03-31 | −kr47.84B | — | — |
| Q4 2025 | 2025-12-31 | −kr43.21B | kr12.62B | — |
| Q3 2025 | 2025-09-30 | −kr52.48B | — | — |
| Q2 2025 | 2025-06-30 | −kr44.82B | — | — |
| Q4 2024 | 2024-12-31 | −kr55.83B | −kr25.82B | — |
| Q4 2023 | 2023-12-31 | −kr30.01B | −kr17.26B | — |
| Q4 2022 | 2022-12-31 | −kr12.75B | kr1.18B | — |
| Q4 2021 | 2021-12-31 | −kr13.92B | −kr9.46B | — |
| Q4 2020 | 2020-12-31 | −kr4.46B | — | — |
Novo Nordisk A S working capital trends
Over the last five fiscal years, Novo Nordisk A S's working capital decreased from −kr4.46B to −kr43.21B, a change of −kr38.74B. The latest reported quarter, Q2 2026, shows −kr30.39B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...